



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:

Orville G. KOLTERMAN *et al.*

Appln. No.: 09/756,690

Filed: January 9, 2001

For: Use of Exendins and Agonists  
Thereof for Modulation of  
Triglyceride Levels and Treatment  
of Dyslipidemia

Art Unit: 1646

Examiner: Dong JIANG

Confirmation No.: 4666

Atty. Docket: 18528.451 / 249/124

**Supplemental Information Disclosure Statement**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The attention of the Examiner is invited to the references listed on the attached Form PTO-1449. Copies of the listed references are submitted herewith.

**Certification and/or Fee**

Applicants certify that each of the documents listed on the attached Form PTO-1449 was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement.

Because this Information Disclosure Statement is being submitted after the mailing date of a final action but before the payment of the issue fee in the above-captioned application, a fee

08/03/2005 SZEWDIE1 00000158 09756690

01 FC:1806 180.00 DA

of \$180.00 is due pursuant to 37 C.F.R. § 1.17(p). Authorization to charge the official fees for this filing is given in the accompanying transmittal letter.

Respectfully submitted,


A handwritten signature in black ink, appearing to read "D. R. Marsh". The signature is fluid and cursive, with the first name "D" being particularly large and stylized.

David R. Marsh (Reg. No. 41,408)  
Thomas E. Holsten (Reg. No. 46,098)

Date: August 2, 2005

ARNOLD & PORTER LLP  
555 Twelfth Street, N.W.  
Washington, D.C. 20004-1206  
(202) 942-5000 telephone  
(202) 942-5999 facsimile

FORM PTO-1449  
INFORMATION DISCLOSURE STATEMENT



ATTY. DOCKET NO.

18528.451 / 249/124

APPLICATION NO.

09/756,690

APPLICANTS

Orville G. KOLTERMAN *et al.*

FILING DATE

January 9, 2001

GROUP

1646

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	REFERENCE PROVIDED*
	AA1				
	AB1				
	AC1				
	AD1				
	AE1				
	AF1				

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	REFERENCE PROVIDED*	TRANSLATION
	AG1	WO 99/07404 A1	02/1999	PCT		Yes No
	AH1	WO 99/25727 A2	05/1999	PCT		Yes No
	AI1	WO 99/25728 A1	05/1999	PCT		Yes No
	AJ1	WO 01/04156 A1	01/2001	PCT		Yes No
	AK1					Yes No
	AL1					Yes No
	AM1					Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

REFERENCE PROVIDED\*

	AN1		
	AO1		
	AP1		
	AQ1		

EXAMINER

DATE CONSIDERED

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

\*Copies of the listed references are either submitted herewith or were previously cited by or submitted to, the Office in a prior application. Pursuant to 37 C.F.R. § 1.97(d) and MPEP §609, the indicated reference may have been previously cited by or submitted to, the Office in a prior application, where the prior application is identified by its U.S. Application Number in this Information Disclosure Statement.

COPY

Patent  
015110.0027.UTL

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Kolterman, et al.

Serial No.: 09/756,690

Filed: January 9, 2001

For: USE OF EXENDINS AND AGONISTS THEREOF  
FOR MODULATION OF TRIGLYCERIDE LEVELS AND  
TREATMENT OF DYSLIPIDEMIA

Group Art Unit: 1614

Examiner: TBA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the Applicants' duty under 37 CFR 1.56, the following information is brought to the attention of the Examiner. The items are listed on the attached Form PTO-1449 and copies are enclosed for the convenience of the Examiner. The listed references were cited in an International Search Report (copy enclosed) from a foreign patent office in a counterpart foreign application.

The items identified in this Supplemental Information Disclosure Statement (Supplemental IDS) may or may not be "material" pursuant to 37 CFR 1.56 and the submission thereof by Applicants shall not be

CERTIFICATE OF MAILING  
(37 C.F.R. §1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as First Class Mail in an envelope addressed to the Commissioner for Patents, Washington, D.C. 20231.

May 22, 2001  
Date of Deposit

Laura Sullivan  
Name of Person Mailing Paper

Laura Sullivan  
Signature of Person Mailing Paper

construed as an admission that any such patent, publication or other information referred to therein is material or considered to be material (37 CFR 1.97(h)), or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention unless specifically designated by Applicants as such.

The filing of this Supplemental IDS shall not be construed to mean that a search has been made or that no other material information, as defined in 37 CFR 1.56, exists.

This Supplemental IDS is believed to be timely in that it is being submitted under 37 CFR 1.97(b)(3) before the mailing of a first Office Action on the merits, whereby no fee is required. However, if counsel for Applicant is in error in this regard, the Commissioner is authorized to charge any required fee to counsel's Deposit Account No. 50-1273.

Respectfully submitted,

BROBECK, PHLEGER & HARRISON, LLP

Dated: \_\_\_\_\_

5/24/01

By: \_\_\_\_\_

Edward O. Kreusser  
Reg. No. 38,523

Brobeck, Phleger & Harrison LLP  
12390 El Camino Real  
San Diego, CA 92130  
Phone (858) 720-2500  
Fax (858) 720-2555

<b>FORM PTO-1449</b>  <b>LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT</b>  (Use several sheets if necessary)	<b>ATTY. DOC. NO.</b> 030639.0027.UTL	<b>SERIAL NO.</b> 09/756,690
	<b>APPLICANT:</b> Kolterman, et al.	
	<b>FILING DATE:</b> January 9, 2001	<b>GROUP:</b> TBA

**COPY**

U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE	

FOREIGN PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION		
						YES	NO	
AA	98/30231	16.07.98	WO					
AB	98/05331	12.02.98	WO					
AC	00/66629	9.11.00	WO					
AD	99/30706	24.6.99	WO					
AE	99/62872	9.12.99	WO					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)		
AF	Young, et al., "Glucose Lowering and Insulin-sensitizing Actions of Exendin-4 Studies in Obese Diabetic (OB/OB, DB/DB) Mice, Diabetic Fatty Zucker Rats, and Diabetic Rhesus Monkeys (Macaca Mulatta)," Diabetes, 48:1026-1034 (1999)	
AG	Kolterman, et al., "Five-day dosing of synthetic exendin-4 (AC2993) in people with type 2 diabetes reduces post-prandial glucose, glucagon, and tryglyceride concentrations," Diabetologia, 43:A189 (2000)	

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include a copy of this form with next communication to applicant	